All In Biotech

Drug Trial Radar · NCT02867813

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease

Last checked: Nov 20, 2026Latest source record: Apr 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,035

Actual

Start

Sep 2, 2016

Primary completion

Mar 21, 2022

Study completion Mar 21, 2022

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).

Conditions

  • Dyslipidemia

Interventions

  • EvolocumabBiological

    subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced an Adverse EventTime frame: Up to 5 years

Locations

198 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Banning, California

  • Research Site

    Long Beach, California

  • Research Site

    Oceanside, California

  • Research Site

    Oxnard, California

  • Research Site

    Palm Springs, California

  • Research Site

    Roseville, California

  • Research Site

    San Diego, California

  • Research Site

    San Pedro, California

  • Research Site

    Tarzana, California

  • Research Site

    Torrance, California

  • Research Site

    Valley Village, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Littleton, Colorado

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Crystal River, Florida

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Largo, Florida

  • Research Site

    Miami, Florida

  • Research Site

    New Port Richey, Florida

  • Research Site

    Pensacola, Florida

  • Research Site

    Ponte Vedra Beach, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Athens, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Augusta, Georgia

  • Research Site

    Dunwoody, Georgia

  • Research Site

    Gainesville, Georgia

  • Research Site

    Savannah, Georgia

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.